These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota. Wang Y, Tong Q, Ma SR, Zhao ZX, Pan LB, Cong L, Han P, Peng R, Yu H, Lin Y, Gao TL, Shou JW, Li XY, Zhang XF, Zhang ZW, Fu J, Wen BY, Yu JB, Cao X, Jiang JD. Signal Transduct Target Ther; 2021 Feb 24; 6(1):77. PubMed ID: 33623004 [Abstract] [Full Text] [Related]
23. Berberine alleviates intestinal barrier dysfunction in glucolipid metabolism disorder hamsters by modulating gut microbiota and gut-microbiota-related tryptophan metabolites. Chen Y, Hao Z, Zhao H, Duan X, Jia D, Li K, Yang Y, Cui H, Gao M, Zhao D. J Sci Food Agric; 2023 Feb 24; 103(3):1464-1473. PubMed ID: 36168925 [Abstract] [Full Text] [Related]
27. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. Yu M, Alimujiang M, Hu L, Liu F, Bao Y, Yin J. Int J Biol Sci; 2021 Feb 24; 17(7):1693-1707. PubMed ID: 33994854 [Abstract] [Full Text] [Related]
29. Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis. Yue SJ, Liu J, Wang WX, Wang AT, Yang XY, Guan HS, Wang CY, Yan D. Biomed Pharmacother; 2019 Aug 24; 116():109002. PubMed ID: 31154270 [Abstract] [Full Text] [Related]
31. The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression. Yang YN, Wang QC, Xu W, Yu J, Zhang H, Wu C. Biomed Pharmacother; 2022 Nov 24; 155():113749. PubMed ID: 36174380 [Abstract] [Full Text] [Related]
32. Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function. Shan YQ, Zhu YP, Pang J, Wang YX, Song DQ, Kong WJ, Jiang JD. Biol Pharm Bull; 2013 Nov 24; 36(10):1562-9. PubMed ID: 23924821 [Abstract] [Full Text] [Related]
34. Enhancing effects of chitosan and chitosan hydrochloride on intestinal absorption of berberine in rats. Chen W, Fan D, Meng L, Miao Y, Yang S, Weng Y, He H, Tang X. Drug Dev Ind Pharm; 2012 Jan 24; 38(1):104-10. PubMed ID: 21774632 [Abstract] [Full Text] [Related]
38. Comparison of Berberine Bioavailability between Oral and Rectal Administrations in Rats. Mori N, Oda K, Takakura H, Tanaka Y, Yokooji T, Murakami T. Biol Pharm Bull; 2023 Jan 24; 46(11):1639-1642. PubMed ID: 37914368 [Abstract] [Full Text] [Related]
39. In vitro assessment of the glucose-lowering effects of berberrubine-9-O-β-D-glucuronide, an active metabolite of berberrubine. Yang N, Sun RB, Chen XL, Zhen L, Ge C, Zhao YQ, He J, Geng JL, Guo JH, Yu XY, Fei F, Feng SQ, Zhu XX, Wang HB, Fu FH, Aa JY, Wang GJ. Acta Pharmacol Sin; 2017 Mar 24; 38(3):351-361. PubMed ID: 28042874 [Abstract] [Full Text] [Related]